Summary of ASH 2018

Jack Aiello |

December 4, 2018 Before presenting my ASH summary, I’ll mention a late-breaking abstract presentation that I was unable to attend early this morning focused on a phase III trial using Darzalex (daratumumab) in front-line therapy plus Rev-dex versus Rev-dex only for transplant-ineligible patients. The abstract # LBA-2 showed that the addition of Dara decreased the […]

New Knowledge and/or Reinforced Knowledge

Tiffany Williams |

This is my 3rd ASH attendance and the first time I feel that I can follow the flow and content with a greater degree of clarity and ease. There is so much information that is available on myeloma. As I sat in meetings yesterday and today, I was intrigued by the number of myeloma providers […]

Day 0 – Symposium Day at ASH2018

Jack Aiello |

Friday, November 30, 2018 November 30th is actually the day before ASH officially begins, often called “Symposium” day. However, my first session was last night’s Bone Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup MRD and Immune Profiling Meeting, a group focused supporting myeloma clinical trials involving transplants and immunotherapies. There were probably 100 […]